NCT03943602Unknown2 期
Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC): an Open-label, Single-center, Phase 2, Single-arm Trial (CaboPen)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano1 个研究点 分布在 1 个国家目标入组 37 人开始时间: 2019年8月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 37
- 试验地点
- 1
- 主要终点
- response -rate by RECIST v1.1 criteria
研究概览
简要总结
Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): an open-label, single-center, phase 2, single-arm trial (CaboPen)
详细描述
an open-label, single-center, phase 2, single-arm trial
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •ECOG (Eastern Cooperative Oncology Group) performance status 0-1
- •Cytologically or histologically proven diagnosis of PSCC.
- •Histologically (Tru-cut biopsy) proven diagnosis of loco-regional nodal disease will be required in all cases except for those with clinical contraindications.
- •Uni- or bidimensionally measurable disease as defined by RECIST v1.1 criteria.
- •Clinical stage N2-3 and/or M1 (TNM 2002).
- •Locoregional relapse after prior major surgery/ies (either single or multiple).
- •No prior systemic therapy except for the administration of VBM (Vinblastine, Bleomycin, Methotrexate) chemotherapy for superficial disease if administered at least 6 months prior to study enrolment.
- •Adequate organ and marrow function .
- •Patients must be accessible for treatment and follow up as well as they must be willing and capable to comply with the requirements of the study. Patients registered on this trial must be treated and followed at the study sponsor site.
排除标准
- •History of any one or more of the following cardiovascular conditions within the past 6 months:
- •Cardiac angioplasty or stenting.
- •Myocardial infarction.
- •Unstable angina.
- •Coronary artery by-pass graft surgery.
- •Symptomatic peripheral vascular disease.
- •Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA).
- •Cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin are permitted during the study but should be used with caution - please refer to the study drug IB).
- •Screening ECG with a QTc>450 msec, congenital long QT syndrome, history of sustained ventricular tachycardia, history of ventricular fibrillation or torsade de pointes, bradycardia defined as heart rate < 50 bpm (patients with a pacemaker and heart rate > 50 bpm are eligible).
- •Uncontrolled hypertension.
- •History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 6 months ior to first dose of study drug.
- •History of HIV infection or active chronic hepatitis B or C.
- •Active clinically serious infections (> grade 2 NCI-CTC version 5.0).
- •Patients with seizure disorder requiring medication (such as steroids or anti-epileptics).
- •Patients undergoing renal dialysis
- •Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT treated basal cell carcinoma or any cancer curatively treated > 5 years prior to study entry.
- •History of clinically-significant gastrointestinal bleeding, inflammatory bowel disease, and other GI disorders associated with high risk of perforation or fistula formation or any other condition.
- •Rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.
- •Major surgery within 12 weeks before the first dose of study treatment. Complete wound healing from major surgery must have occurred 1 month before the first dose of study treatment. Minor surgery (including uncomplicated tooth extractions) within 28 days before the first dose of study treatment with complete wound healing at least 10 days before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.
- •History of allogenic organ solid transplantation.
- •Fertile males not willing to use a highly effective method of contraception or whose female partner is not using a highly effective contraception protection.
- •Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
- •Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.
- •Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug.
- •Hemoptysis >=2.5 ml red blood within 3 months before treatment, signs indicative of pulmonary hemorrhage, cavitating pulmonary lesion, tumor invading major blood vessels and/or GI tract, endotracheal or endobronchial tumors History of clinically-significant gastrointestinal bleeding, inflammatory bowel disease, or any other condition among those listed in the full protocol.
- •Patients unable to swallow oral medications.
- •Concomitant anticoagulation with oral anticoagulants or platelet inhibitors.
- •History of cerebrovascular accident, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.
研究组 & 干预措施
Cabozantinib
Experimental
Cabozantinib will be administered orally at a dose of 60 mg/day continuously until 28 days prior to planned surgery or at time of the evidence of disease progression or onset of unacceptable toxicity.
干预措施: Cabozantinib (Drug)
结局指标
主要结局
response -rate by RECIST v1.1 criteria
时间窗: 40 months
Assessment of response-rate by RECIST v1.1. Complete response + partial response
次要结局
- Pathologic complete response (pCR)(40 months)
- Incidence of treatment-Emergent Adverse Event(safety and tolerability)(40 months)
- Progression-free survival (PFS).(40 months)
- Overall Survival (OS).(40 months)
- Variations of the Quality of Life(40 months)
- FDG-PET/CT response rate according to EORTC criteria(40 months)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): an open-label, single-center, phase 2, single-arm trial (CaboPen)Patients with advanced penile squamous cell carcinoma (PSCC)MedDRA version: 21.1Level: LLTClassification code 10049570Term: Penile neoplasm NOSSystem Organ Class: 100000004864EUCTR2017-001963-19-ITFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI37
终止
2 期
Cabozantinib in Advanced Salivary Gland Cancer PatientsSalivary Gland CancerNCT03729297Radboud University Medical Center25
终止
2 期
Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)Penile Squamous Cell Carcinoma Stage IVNCT02279576Spanish Oncology Genito-Urinary Group4
已完成
2 期
Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment FailureAdvanced/Metastatic Cervical CancerNCT04205799Centre Francois Baclesse57
已完成
2 期
Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the PenisPenile NeoplasmsCarcinoma, Squamous CellNCT01728233Fondazione IRCCS Istituto Nazionale dei Tumori, Milano32